Effectiveness of CFTR Modulators According to Co-therapy (MODUCO)

Civil Hospices of Lyon

Status: Not yet enrolling

Conditions: Cystic Fibrosis

Treatments: Drug: Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)

Study type: Observational

Funder types: Other

Identifiers

NCT05663255

69HCL20_0066

Details and patient eligibility

About

Unless CFTR modulators are highly effective, the introduction of CFTR (Cystic fibrosis transmembrane conductance regulator) modulators could lead to concomitant reduction or discontinuation of respiratory co-therapies in real-life. Such reduction/discontinuation of respiratory co-therapies could lead to an overall decrease of the effectiveness of CF care.

MODUCO study aims: 1) to compare the clinical effectiveness on lung function and pulmonary exacerbation of CFTR modulator during the year of initiation, according to level of co-therapy among CF patients; 2) to describe the nature and level of respiratory co-therapies (azithromycin, RhDNase, inhaled antibiotics) in the year before the initiation of CFTR modulator; 3) to describe the changes in respiratory co-therapies during the first and the second year following the initiation of CFTR modulator and compare between the two CFTR modulators; 4) to describe adherence to CFTR modulator during the first and the second year following its initiation; 5) to study the association between the nature of respiratory co-therapies and adherence to CFTR modulator during the first and the second year following its initiation.

A national population-based comparative effectiveness study will be conducted, based on retrospective analysis of clinical and prescription data of the French CF registry linked with the French national health data system (SNDS).

Enrollment: 1,990 estimated patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • CF patients aged 6 years and more,
• Treated at least 6 months by ivacaftor or lumacaftor/ivacaftor or elexacaftor/tezacaftor/ivacaftor,
• Included in the French CF registry,
• For whom probabilistic matching with the SNDS database has succeeded.

Exclusion criteria

• none

Trial design

1,990 participants in 2 patient groups

Exposed group

Description:

Patients treated with CFTR modulator with at least the discontinuation of one respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics) during the year of initiation (A0) of CFTR modulator.

Treatment:

Drug: Discontinuation of respiratory co-therapy (azithromycin, RhDNase, or inhaled antibiotics)

Control group

Description:

Patients treated with CFTR modulator without any discontinuation of respiratory co-therapy (azithromycin, RhDNase, inhaled antibiotics) during the year of initiation (A0) of CFTR modulator.